Jennifer Kaivers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Kaivers has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
R. Haas
Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
3 shared publicationsU. Germing
Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
3 shared publicationsB. Betz
Institut für Humangenetik, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
2 shared publicationsB. Hildebrandt
Department of Human Genetics, University Hospital Düsseldorf, Germany
2 shared publicationsC. Ganster
Clinics of Hematology and Medical Oncology, University Medical Center Göttingen, Germany
2 shared publicationsC. Rautenberg
Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
2 shared publications
Latest Publications
- Open Access
- 18 July 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (14) , 7629
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS.
- 18 July 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (14) , 7629
Open AccessGuidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS.
- 2 February 2021
- Published by Springer Nature in best practice onkologie
- Vol. 16 (3) , 126-128
Erratum zu: Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
- 2 February 2021
- Published by Springer Nature in best practice onkologie
- Vol. 16 (3) , 126-128
Erratum zu: Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
- 4 January 2021
- Published by Springer Nature in best practice onkologie
- Vol. 16 (1-2) , 20-28
Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
- 4 January 2021
- Published by Springer Nature in best practice onkologie
- Vol. 16 (1-2) , 20-28
Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
- Open Access
Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
To provide long-term outcome data and predictors for response and survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated with first-line azacitidine (Aza) salvage therapy at our center. Patients were treated for molecular (39%) or hematologic relapse (61%), with a median of 5 cycles of Aza and at least one donor lymphocyte infusion in 70% of patients. Overall response was 46%, with 41% achieving complete (CR) and 5% achieving partial remission. CR was achieved after a median of 4 cycles and lasted for a median of 11 months (range 0.9 to 120 months). With a median follow-up of 22 months (range: 1 to 122 months), the 2-year survival rate was 38% ± 9%, including 17 patients with ongoing remission for >5 years. Based on results from multivariate analyses, molecular relapse and time to relapse were integrated into a score, clearly dividing patients into 3 subgroups with CR rates of 71%, 39%, and 29%; and 2-year survival rates of 64%, 38%, and 27%, respectively. In the subgroup of MDS and secondary AML, receiving upfront transplantation was associated with superior response and survival, and therefore pretransplant strategy was integrated together with relapse type into a MDS–sAML-specific score. Overall, Aza enables meaningful responses and long-term survival, which is a predictable with a simple-to-use scoring system.
Open AccessPrediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
To provide long-term outcome data and predictors for response and survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated with first-line azacitidine (Aza) salvage therapy at our center. Patients were treated for molecular (39%) or hematologic relapse (61%), with a median of 5 cycles of Aza and at least one donor lymphocyte infusion in 70% of patients. Overall response was 46%, with 41% achieving complete (CR) and 5% achieving partial remission. CR was achieved after a median of 4 cycles and lasted for a median of 11 months (range 0.9 to 120 months). With a median follow-up of 22 months (range: 1 to 122 months), the 2-year survival rate was 38% ± 9%, including 17 patients with ongoing remission for >5 years. Based on results from multivariate analyses, molecular relapse and time to relapse were integrated into a score, clearly dividing patients into 3 subgroups with CR rates of 71%, 39%, and 29%; and 2-year survival rates of 64%, 38%, and 27%, respectively. In the subgroup of MDS and secondary AML, receiving upfront transplantation was associated with superior response and survival, and therefore pretransplant strategy was integrated together with relapse type into a MDS–sAML-specific score. Overall, Aza enables meaningful responses and long-term survival, which is a predictable with a simple-to-use scoring system.
- 2 August 2020
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 20 (8) , 703-714
Improving the accuracy of prognostication in chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia (CMML) is a hematological malignancy that is extremely variable regarding its clinical course. It may present either as a chronic disorder with mild symptoms and low...
- 2 August 2020
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 20 (8) , 703-714
Improving the accuracy of prognostication in chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia (CMML) is a hematological malignancy that is extremely variable regarding its clinical course. It may present either as a chronic disorder with mild symptoms and low...
- 23 July 2018
- Published by Elsevier in Leukemia Research
- Vol. 72, 27-33
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
- 23 July 2018
- Published by Elsevier in Leukemia Research
- Vol. 72, 27-33
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
- 1 April 2017
- Published by Elsevier in Leukemia Research
- Vol. 55, S108-S109
Significance of Molecular and Cytogenetic TP53 Status in MDS with Complex Karyotypes
- 1 April 2017
- Published by Elsevier in Leukemia Research
- Vol. 55, S108-S109
Significance of Molecular and Cytogenetic TP53 Status in MDS with Complex Karyotypes